EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human Studies

Pauline Nettesheim, Krishna C Vadodaria iD, Kimberly E Vanover, Laura G J M Borghans, Estibaliz Arce, William Brubaker, Stephen Cunningham, Stephanie Parks, Jordi Serrats, Vikram Sudarsan, Eve Taylor, Erica Klaassen und 2 weitere

Cells · 2025

DOI: 10.3390/cells14201575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Pauline Nettesheim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, 2333 CL Leiden, The Netherlands. Hauptthemen laut MEDLINE: Receptors, GABA-A, Anti-Anxiety Agents. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engrail Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gamma-aminobutyric acid type A receptors (GABAARs) are pentameric ligand-gated ion channels essential for inhibitory neurotransmission in the central nervous system. Subtype-specific expression patterns of GABAAR subunits underlie their diverse roles in regulating anxiety, motor function, and sedation. While non-selective GABAAR positive allosteric modulators (PAMs), such as benzodiazepines, are clinically effective anxiolytic drugs, their non-selective activity across α1/2/3/5 subunit-containing GABAARs leads to sedation, cognitive impairment, and risk of dependence. To address this, we evaluated ENX-102, a novel GABAAR PAM, which exhibits selectivity for α2/3/5 subunits. In rodents, ENX-102 demonstrated dose-dependent anxiolytic-like activity following acute and sub-chronic administration, without sedation. ENX-102 exhibited a dose-dependent quantitative electroencephalography (qEEG) spectral signature in rodents that was distinct from that of benzodiazepines. In a double-blind, placebo-controlled, multiple-ascending dose study in healthy human volunteers, ENX-102 was evaluated using the NeuroCart, a CNS test battery including saccadic peak velocity (SPV), adaptive tracking, pupillometry, body sway, the Bond and Lader Visual Analog Scale (VAS), the Visual Verbal Learning Task (VVLT), and qEEG. ENX-102 produced reductions in SPV that were indicative of central target engagement, with minimal effects on alertness and motor coordination, which is consistent with subtype-selective GABAAR targeting. Notably, qEEG revealed increased β-band power and decreased δ- and θ-band activity, which were distinct from the spectral profile of non-selective PAMs, supporting translational alignment with preclinical findings. Across dose levels, ENX-102 was well tolerated and exhibited favorable pharmacokinetics. These results support further clinical development of ENX-102 as a next-generation GABAAR subtype-selective anxiolytic drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, GABA-AAnti-Anxiety AgentsHumansAnimalsMaleRatsBiomarkersFemaleMiceAdultTranslational Research, BiomedicalRats, Sprague-DawleyElectroencephalographyDouble-Blind MethodYoung Adult

Stichwörter der Autor:innen

ENX-102GABAA receptorbenzodiazepinesubtype-selectivetranslational

Substanzen

Receptors, GABA-ABiomarkersAnti-Anxiety Agents

Autor:innen und Institutionen

  • Centre for Human Drug Research, 2333 CL Leiden, The Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZG Leiden, The Netherlands.
  • Engrail Therapeutics, Inc., San Diego, CA 92130, USA.
  • Department of Psychiatry, Leiden University Medical Center, 2333 ZG Leiden, The Netherlands.

ORCID-Profile: Krishna C Vadodaria, Frederik E Stuurman

Förderung

  • Engrail Therapeutics, Inc.

Zitieren

APA

Nettesheim, P., Vadodaria, K. C., Vanover, K. E., Borghans, L. G. J. M., Arce, E., Brubaker, W., Cunningham, S., Parks, S., Serrats, J., Sudarsan, V., Taylor, E., Klaassen, E., Stuurman, F. E., & Jacobs, G. E. (2025). Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human Studies. Cells. https://doi.org/10.3390/cells14201575

Vancouver

Nettesheim P, Vadodaria KC, Vanover KE, Borghans LGJM, Arce E, Brubaker W, et al. Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human Studies. Cells. 2025. doi:10.3390/cells14201575

BibTeX
@article{Nettesheim2025,
  author = {Nettesheim, Pauline and Vadodaria, Krishna C and Vanover, Kimberly E and Borghans, Laura G J M and Arce, Estibaliz and Brubaker, William and Cunningham, Stephen and Parks, Stephanie and Serrats, Jordi and Sudarsan, Vikram and Taylor, Eve and Klaassen, Erica and Stuurman, Frederik E and Jacobs, Gabriel E},
  title = {Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human Studies},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14201575}
}
Kostenlos starten →